{"id":"W2890014497","doi":"10.1200/jco.2018.36.15_suppl.4500","title":"Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Clinical endpoint; Internal medicine; Renal cell carcinoma; Oncology; Response Evaluation Criteria in Solid Tumors; Progressive disease; Adverse effect; Surgery; Urology; Clinical trial; Disease; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003114085,0.0007282062,0.001089142,0.0006149558,0.0006876359,0.00108788,0.0006378648,0.0006982893,0.00286489],"category_scores_gemma":[0.002215731,0.0003311893,0.001328902,0.0006723955,0.0004357249,0.0008090533,0.0008143721,0.00117436,0.0009347947],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001174187,"about_ca_system_score_gemma":0.002088323,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004723083,"about_ca_topic_score_gemma":0.006026312,"domain_scores_codex":[0.9990707,0.0003998748,0.00007091433,0.0001514599,0.0001608883,0.0001462193],"domain_scores_gemma":[0.9981753,0.0002823221,0.0003669842,0.0003227626,0.0002433414,0.0006093897],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4886997,0.05399267,0.2855554,0.001218878,0.005534644,0.001197031,0.001166797,0.003270634,0.01576604,0.0004816476,0.03526742,0.1078491],"study_design_scores_gemma":[0.1984613,0.1958669,0.5579647,0.0002465767,0.004385621,0.002978602,0.0007963991,0.003734152,0.008038683,0.0004920047,0.0268885,0.0001464849],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987063,0.0009663023,0.0003002557,0.0001896762,0.00003643762,0.001172118,0.008697107,0.00006400414,0.00151109],"genre_scores_gemma":[0.94869,0.001098966,0.001407767,0.0008579723,0.0001771484,0.001388233,0.0442229,0.00004541881,0.002111645],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004723083,"threshold_uncertainty_score":0.01646906,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0781875072256028,"score_gpt":0.4026770833521769,"score_spread":0.3244895761265741,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}